Serum Tenascin-C and Abdominal Aortic Calcification in Peritoneal Dialysis Patients
Department of Nephrology,Qingdao Municipal Hospital of Qingdao University,Qingdao 266011,China
*Corresponding author:WAN Meiyan,Chief physician;E-mail:wanmeiyan07@163.com
[1]PALOIAN N J,GIACHELLI C M.A current understanding of vascular calcification in CKD[J].Am J Physiol Renal Physiol,2014,307(8):F891-900.DOI:10.1152/ajprenal.00163.2014.
[2]WANG A Y,BRIMBLE K S,BRUNIER G,et al.ISPD cardiovascular and metabolic guidelines in adult peritoneal Dialysis patients partⅠ- assessment and management of various cardiovascular risk factors[J].Perit Dial Int,2015,35(4):379-387.DOI:10.3747/pdi.2014.00279.
[3]DE JAGER D J,GROOTENDORST D C,JAGER K J,et al.Cardiovascular and noncardiovascular mortality among patients starting Dialysis[J].JAMA,2009,302(16):1782-1789.DOI:10.1001/jama.2009.1488.
[4]SMITH E R.Vascular calcification in uremia:new-age concepts about an old-age problem[J].Methods Mol Biol,2016,1397:175-208.DOI:10.1007/978-1-4939-3353-2_13.
[5]MIDWOOD K S,CHIQUET M,TUCKER R P,et al.Tenascin-C at a glance[J].J Cell Sci,2016,129(23):4321-4327.DOI:10.1242/jcs.190546.
[6]OZKAN G,ULUSOY S,GUVERCIN B,et al.A new player in chronic kidney disease mineral and bone disorder:tenascin-C[J].Int J Artif Organs,2015,38(9):481-487.DOI:10.5301/ijao.5000436.
[7]MORGAN J M,WONG A,YELLOWLEY C E,et al.Regulation of tenascin expression in bone[J].J Cell Biochem,2011,112(11):3354-3363.DOI:10.1002/jcb.23265.
[8]Kidney Disease:Improving Global Outcomes(KDIGO) CKD-MBD Update Work Group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J].Kidney Int Suppl (2011),2017,7(1):1-59.DOI:10.1016/j.kisu.2017.04.001.
[9]KAUPPILA L I,POLAK J F,CUPPLES L A,et al.New indices to classify location,severity and progression of calcific lesions in the abdominal aorta:a 25-year follow-up study[J].Atherosclerosis,1997,132(2):245-250.DOI:10.1016/s0021-9150(97)00106-8.
[10]ORTIZ A,COVIC A,FLISER D,et al.Epidemiology,contributors to,and clinical trials of mortality risk in chronic kidney failure[J].Lancet,2014,383(9931):1831-1843.DOI:10.1016/S0140-6736(14)60384-6.
[11]LIU J Y,ZHANG L,ZHOU Y,et al.Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease[J].Int Urol Nephrol,2016,48(8):1313-1319.DOI:10.1007/s11255-016-1291-2.
[12]LIU Z H,China Dialysis Calcification Study (CDCS) Group.Vascular calcification burden of Chinese patients with chronic kidney disease:methodology of a cohort study[J].BMC Nephrol,2015,16:129.DOI:10.1186/s12882-015-0132-3.
[13]TOUSSAINT N D,PEDAGOGOS E,LAU K K,et al.Lateral lumbar X-ray assessment of abdominal aortic calcification in Australian haemodialysis patients[J].Nephrology(Carlton),2011,16(4):389-395.DOI:10.1111/j.1440-1797.2010.01420.x.
[14]HONKANEN E,KAUPPILA L,WIKSTR M B,et al.Abdominal aortic calcification in Dialysis patients:results of the CORD study[J].Nephrol Dial Transplant,2008,23(12):4009-4015.DOI:10.1093/ndt/gfn403.
[15]OKUNO S,ISHIMURA E,KITATANI K,et al.Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients[J].Am J Kidney Dis,2007,49(3):417-425.DOI:10.1053/j.ajkd.2006.12.017.
[16]王中群,戴俏武,邵晨,等.血管钙化的骨调控机制新进展[J].中华心血管病杂志,2017,45(1):78-80.DOI:10.3760/cma.j.issn.0253-3758.2017.01.017.
[17]SHANAHAN C M,CROUTHAMEL M H,KAPUSTIN A,et al.Arterial calcification in chronic kidney disease:key roles for calcium and phosphate[J].Circ Res,2011,109(6):697-711.DOI:10.1161/circresaha.110.234914.
[18]SATO A,AONUMA K,IMANAKA-YOSHIDA K,et al.Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction[J].J Am Coll Cardiol,2006,47(11):2319-2325.DOI:10.1016/j.jacc.2006.03.033.
[19]IHIDA-STANSBURY K,MCKEAN D M,LANE K B,et al.Tenascin-C is induced by mutated BMP type Ⅱ receptors in familial forms of pulmonary arterial hypertension[J].Am J Physiol Lung Cell Mol Physiol,2006,291(4):L694-702.DOI:10.1152/ajplung.00119.2006.
[20]SAWADA Y,ONODA K,IMANAKA-YOSHIDA K,et al.Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis[J].Cardiovasc Res,2007,74(3):366-376.DOI:10.1016/j.cardiores.2007.02.028.
[21]TRESCHER K,THOMETICH B,DEMYANETS S,et al.Type A dissection and chronic dilatation:tenascin-C as a key factor in destabilization of the aortic wall[J].Interact Cardiovasc Thorac Surg,2013,17(2):365-370.DOI:10.1093/icvts/ivt204.
[22]JIAN B,JONES P L,LI Q,et al.Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis[J].Am J Pathol,2001,159(1):321-327.DOI:10.1016/S0002-9440(10)61698-7.
[23]BARDEESI A S A,GAO J W,ZHANG K,et al.A novel role of cellular interactions in vascular calcification[J].J Transl Med,2017,15(1):95.DOI:10.1186/s12967-017-1190-z.
[24]LI C Z,CUI Y Z,LUAN J,et al.Tenascin C affects mineralization of SaOS2 osteoblast-like cells through matrix vesicles[J].Drug Discov Ther,2016,10(2):82-87.DOI:10.5582/ddt.2016.01009.
[25]OH D J,KIM H R,LEE M K,et al.Profile of human β-defensins 1,2 and proinflammatory cytokines(TNF-α,IL-6) in patients with chronic kidney disease[J].Kidney Blood Press Res,2013,37(6):602-610.DOI:10.1159/000355740.
[26]KUGLER E,COHEN E,GOLDBERG E,et al.C reactive protein and long-term risk for chronic kidney disease:a historical prospective study[J].J Nephrol,2015,28(3):321-327.DOI:10.1007/s40620-014-0116-6.
[27]LIABEUF S,BARRETO DV,KRETSCHMER A,et al.High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients[J].Atherosclerosis,2011,215(1): 116-124.DOI: 10.1016/j.atherosclerosis.2010.11.038.